The CEO and CFO addressed supply chain challenges in orthopedics during an earnings call. They aim to improve product availability despite setbacks, remaining optimistic about recovery by Q4 2024. General surgery business is deemed less affected. Growth is expected in foot and ankle markets and general surgery business.